You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B-cell non-Hodgkin's Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-hodgkin Lymphoma Trial (HY004)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • HY004
  • (no location specified)
Aug 21, 2023

CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

Recruiting
  • CD20-positive B-cell Non-Hodgkin's Lymphoma
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023

B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • (no location specified)
Aug 7, 2023

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

Not yet recruiting
  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
  • (no location specified)
Mar 23, 2023

B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • CB dualCAR-NK19/70
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Jan 4, 2023

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Trial in Isehara, Chuo-ku (tazemetostat)

Completed
Has Results
  • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
  • Isehara, Kanagawa, Japan
  • +1 more
Apr 6, 2022

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Beijing (JS203 for Injection)

Not yet recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • JS203 for Injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 11, 2022

B-cell Non-Hodgkin's Lymphoma Trial (IMM0306, Lenalidomide capsule)

Not yet recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • (no location specified)
Mar 6, 2023

B-cell Non-Hodgkin's Lymphoma Trial (SHR-A1912; R-Chemo)

Not yet recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • SHR-A1912; R-Chemo
  • (no location specified)
Oct 23, 2023

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

Lymphoma, Non-Hodgkin Trial in Perth (DZD8586)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • Perth, Western Australia, Australia
    Linear Clinical Research Ltd
Apr 20, 2023

B-cell Non-Hodgkin Lymphoma (B-NHL) Trial in Austin (UCART20x22, CLLS52)

Recruiting
  • B-cell Non-Hodgkin Lymphoma (B-NHL)
  • UCART20x22
  • CLLS52
  • Austin, Texas
    Sarah Cannon - St. David South Austin Medical Center
Dec 8, 2022

B-Cell Non-Hodgkin Lymphoma, Multiple Myeloma Trial in Duarte (Best Practice, Cognitive Intervention, Comprehensive Geriatric

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • Multiple Myeloma
  • Best Practice
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Sep 19, 2023

Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

Suspended
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 12, 2023

Lymphoma, Non-Hodgkin Trial in China (DZD8586)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Beijing, Beijing, China
  • +5 more
Apr 25, 2023

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    Relapsed or Refractory Mantle Cell Lymphoma (MCL) Trial in Duarte (BAFFR-CAR T cells)

    Recruiting
    • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
    • BAFFR-CAR T cells
    • Duarte, California
      City of Hope Medical Center
    Oct 18, 2022

    NHL, NHL, Relapsed, Adult Trial in United States (CLN-978)

    Recruiting
    • NHL
    • NHL, Relapsed, Adult
    • Birmingham, Alabama
    • +4 more
    May 31, 2023

    B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)

    Recruiting
    • B-Cell Non Hodgkin Lymphoma
    • B-Cell Acute Lymphoblastic Leukemia
    • anti-CD19 CAR T-cells
    • Hanoi, Vietnam
      Vinmec Research Institute of Stem Cell and Gene Technology
    Sep 5, 2023

    Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

    Active, not recruiting
    • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
    • +22 more
    • External Beam Radiation Therapy
    • Orbital Radiation
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 9, 2022

    Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)

    Not yet recruiting
    • Mature B-Cell Non-Hodgkin Lymphoma
    • (no location specified)
    Sep 6, 2022

    LY007 for r/r B-NHL and Exploration of Novel CAR-T Translational

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
      • (no location specified)
      Sep 19, 2023

      Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive

      Active, not recruiting
      • Aggressive B-Cell Non-Hodgkin Lymphoma
      • fractionated first dose rituximab
      • Geneva, Switzerland
        University Hospital Geneva
      Apr 21, 2023